Proliferation activation of pancreatic islet cells by activation of glucose pathway

By regulating the glucose pathway with glucose-stimulated activators, the proliferation of pancreatic islet cells is sustained, addressing the limitations of temporary growth in existing methods and enhancing insulin production for effective diabetes management.

WO2024237210A1PCT designated stage expired Publication Date: 2024-11-21THE UNIV OF TOKYO
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/017478
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-05-10
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current methods for sustaining the proliferation of mature pancreatic islet cells using the Mycl gene are limited by temporary proliferative activity, making long-term growth and insulin production challenging, particularly in diabetes treatment where stable insulin secretion is crucial.

Method used

Regulating the glucose pathway using glucose-stimulated activation pathway activators such as glucose, sucrose, and glucokinase activators to promote and sustain the proliferation of pancreatic islet cells by controlling Mycl gene expression, either through transient expression or alternating high and low glucose concentrations.

Benefits of technology

This approach maintains and enhances the proliferative activity of pancreatic islet cells over a long period, enabling stable insulin production and potential therapeutic benefits for diabetes, including improved glucose control and reduced risk of severe hypoglycemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024017478_21112024_PF_FP_ABST
    Figure JP2024017478_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The purpose of the present invention is to provide a method that sustains proliferation of mature pancreatic islet cells by a Mycl gene and enables continuous induction of proliferation. The present invention provides a method for promoting and / or sustaining, by a glucose stimulation activation pathway activator, the proliferation activity of pancreatic islet cells in which a Mycl gene or a gene product thereof has been introduced or expressed through induction. More specifically, in the method, the Mycl gene includes (1) a nucleic acid having a base sequence represented by SEQ ID NO: 1 or 3, or (2) a nucleic acid that hybridizes with, under stringent conditions, a nucleic acid having a base sequence represented by SEQ ID NO: 1 or 3, and that encodes a polypeptide having the function of sustaining and / or promoting the proliferation activity of pancreatic islet-like cells when expression of the Mycl gene is induced.
Need to check novelty before this filing date? Find Prior Art

Description

Activation of the glucose pathway stimulates proliferation of pancreatic islet cells

[0001] The present invention relates to a method for sustaining and promoting the proliferation of pancreatic islet cells into which the Mycl gene or its gene product has been introduced or into which expression has been induced, by regulating a glucose-activated pathway.

[0002] Global medical expenses for diabetes and its complications are estimated at 90 trillion yen per year, creating a significant social problem. Diabetes can lead to complications such as retinopathy, neuropathy, and nephropathy, and in the final stages, dialysis may be required. Furthermore, in severe cases of end-stage diabetes, where insulin secretion is almost nonexistent, blood glucose control is particularly poor, leading to repeated episodes of severe hypoglycemia that can lead to coma and death. Because the onset of severe hypoglycemia can lead to brain damage sequelae, including dementia, and a worsening prognosis, preventing the onset of severe hypoglycemia is an important clinical challenge. Treatments for diabetes primarily focus on symptomatic treatments, such as the administration of insulin preparations and drugs that suppress glucose absorption, but most of these treatments do not actually treat the diabetes itself.

[0003] Pancreas and islet transplants are performed for patients with poor prognosis, particularly those with poor glycemic control, who suffer from insulin secretion depletion and repeated episodes of severe hypoglycemia. These transplants have demonstrated remarkable benefits, including not only preventing the onset of severe hypoglycemia but also achieving insulin withdrawal and good glycemic control. However, due to a shortage of donors and a limited number of islet isolation facilities, the number of eligible patients is extremely limited. Pancreas and islet transplants are not offered as early intervention treatment options for patients with a simple history of severe hypoglycemia, high-risk groups with insulin secretion depletion, or even patients with standard type 1 diabetes. In 2020, donor islet transplants were covered by insurance as "allogeneic cadaveric islet transplantation." Although treatment outcomes have improved compared to the past, challenges remain, including donor shortages, individual differences in donor islets, and variations in the time and method of islet isolation, resulting in issues with islet quality and yield. These challenges have led to a variety of problems, including a limited number of patients eligible for transplantation, the cancellation of planned islet transplants, and the need for repeated transplants to achieve sufficient therapeutic effects, such as insulin withdrawal. While progress is being made in the development of cell transplantation medicine using insulin-producing cells derived from pluripotent stem cells, a major problem is that these cells are functionally immature. Furthermore, due to the complex differentiation induction process, it is currently difficult to induce differentiation of pluripotent stem cells into endoderm, pancreas, and pancreatic islets at low cost.

[0004] On the other hand, if sufficient quantities of donor islet cells can be expanded, it is expected that a relatively simple manufacturing process and quality control will enable the stable supply of safe, high-quality products at relatively low cost. Furthermore, because it becomes possible to transplant a sufficient amount of high-quality islet cells, a single transplant may be sufficient to achieve a satisfactory therapeutic effect. Furthermore, cryopreserving intermediate and final products enables planned transplantation therapy, minimizing the risk of transplant discontinuation due to an unstable islet supply. Furthermore, if sufficient quantities of islets for transplantation can be stably supplied, it is expected that the range of patients eligible for treatment will expand. Furthermore, if it is possible to expand islet cells derived from pluripotent stem cells, it is expected that the cost of producing pluripotent stem cell-derived islet cells for transplantation will be reduced. From this perspective, it is expected to have a significant impact on diabetes treatment strategies compared to existing therapies. In recent years, Mycl gene transduction has made it possible to induce the proliferation of mature islet cells. It is expected that transplantation medicine will be realized by inducing the proliferation of islet cells using Mycl (Patent Document 1). However, the induction of mature islet cell proliferation by Mycl gene transduction has been limited, resulting in a problem of limited expansion efficiency.

[0005] International Publication No. 2021 / 117840

[0006] Although it has been possible to confer proliferation activity to mature islet cells by expressing the Mycl gene, the proliferation of islets is temporary, and the proliferation activity declines after several passages, making sustained expansion impossible. Therefore, an object of the present invention is to provide a method for sustaining the proliferation of mature islet cells by the Mycl gene, enabling continuous induction of proliferation.

[0007] The present inventors discovered that it is possible to proliferate islet cells and expand mature islet cells over the long term by regulating pathways activated by glucose, such as by activating the proliferation of mature islet cells by the Mycl gene in a glucose concentration-dependent manner, by using a glucokinase activator to activate the proliferation of mature islet cells by the Mycl gene, and by repeatedly stimulating them with short-term high concentrations of glucose, and thus completed the present invention.

[0008] That is, the present invention has the following aspects: [1] A method for promoting and / or sustaining the proliferative activity of pancreatic islet cells into which a Mycl gene or a gene product thereof has been introduced or whose expression has been induced, using a glucose-stimulated activation pathway activator. [2] The method according to [1], wherein the glucose-stimulated activation pathway activator is at least one selected from the group consisting of glucose, sucrose, and glucokinase activators. [3] The method according to [1] or [2], wherein the Mycl gene comprises: (1) a nucleic acid comprising the nucleotide sequence represented by SEQ ID NO: 1 or 3; or (2) a nucleic acid that hybridizes under stringent conditions with a nucleic acid comprising the nucleotide sequence represented by SEQ ID NO: 1 or 3 and encodes a polypeptide that has the function of sustaining and / or promoting the proliferative activity of pancreatic islet-like cells in a glucose concentration-dependent manner when the expression of the Mycl gene is induced. [4] The method of [1] or [2], wherein the Mycl gene product comprises: (1) a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 2 or 4; or (2) a polypeptide having at least 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity with the amino acid sequence represented by SEQ ID NO: 2 or 4, and having the function of sustaining and / or promoting the proliferation activity of pancreatic islet-like cells in a glucose concentration-dependent manner. [5] The method of any of [1] to [4], wherein the Mycl gene is transiently expressed. [6] The method of any of [1] to [5], wherein high and low concentrations of glucose are applied alternately. [7] The method of any of [1] to [6], wherein the pancreatic islet cells are derived from primary pancreatic islet cells isolated from the pancreas, cultured pancreatic islet cells, or stem cells. [8] The method of [7], wherein the stem cells are selected from the group consisting of iPS cells, ES cells, and somatic stem cells.

[0009] According to the present invention, by regulating the pathway activated by glucose, pancreatic islet cells are proliferated and the proliferative activity of pancreatic islet-like cells is maintained for a long period of time, thereby making it possible to treat diabetes or related diseases in which insulin production is desired.

[0010]

[0033] Figure 1 shows the activation of proliferation of Mycl-induced islet cells in vivo by glucose.

[0034] Figure 2 shows the activation of proliferation of Mycl-induced islet cells in vivo by glucose.

[0035] Figure 3 shows the change in proliferation efficiency of Mycl-induced islet cells by glucokinase activator (GKA).

[0036] Figure 4 shows the change in proliferation efficiency of Mycl-induced islet cells by glucokinase inhibitor (GKI).

[0037] Figure 5 shows the activation of proliferation of Mycl-induced islet cells in vivo by glucose.

[0038] Figure 6 shows the decrease in proliferation activity of Mycl-induced islet cells under culture conditions with high glucose concentrations.

[0039] Figure 7 shows the sustained proliferation activity of Mycl-induced islet cells by high-low glucose.

[0039] Figure 8 shows the promotion of proliferation of mature hormone-producing cells by Mycl gene expression.

[0039] Figure 9 shows the efficient induction of β-cell proliferation by coordination of Mycl gene expression and glucose.

[0039] Figure 10 shows the recovery of diabetic mice by long-term culture of islet cells.

[0011] The present invention relates to a method for sustaining and / or promoting the proliferation activity of pancreatic islet cells (hereinafter, sometimes referred to as "pancreatic islet-like cells") in a glucose concentration-dependent manner, into which a Mycl gene or its gene product has been introduced or whose expression has been induced. The present invention is described in detail below.

[0012] 1. Islet-like Cells and Method for Preparing the Same (1) Islet-like Cells As used herein, "islet-like cells" refers to mature islet cells into which the Mycl gene or its gene product has been introduced. Note that, herein, islet-like cells that have transitioned to the proliferation phase due to forced expression of the Mycl gene are sometimes referred to as "islet precursor cell-like cells." Furthermore, by terminating the expression of the Mycl gene, they can be differentiated into pancreatic islet cells, including cells capable of producing insulin (hereinafter also referred to as "insulin-producing cells"). That is, according to the present invention, transient expression of the Mycl gene increases the number of islet-like cells and enables them to differentiate into pancreatic islet cells, including insulin-producing cells. Focusing on the markers expressed in each cell, "islet precursor cell-like cells" are positive for at least one, preferably two, and more preferably three or more, of genes selected from, for example, Fev, Pax4, Cck, CDK4, and Ki67. In addition, when focusing on the proteins expressed, they are also characterized by reduced insulin and glucagon production, particularly compared to that observed in normal pancreatic islets, or by significant somatostatin production.

[0013] (2) Pancreatic Islet Cells "Pancreatic islet cells," also known as islets of Langerhans, refer to endocrine cells that comprise a cell cluster called a pancreatic islet, which controls the endocrine function of the pancreas and accounts for approximately 1-2% of the total cells in the pancreas. In this specification, the term "pancreatic islet cells" is used interchangeably with "mature pancreatic islet cells." Pancreatic islet cells are primarily composed of five types of cells: α cells, β cells, δ cells, ε cells, and PP cells. The primary cells that comprise the cell clusters known as pancreatic islets are β cells. β cells account for approximately 60-80% of pancreatic islet cells and secrete insulin, which enables glucose transport to most cells in the body. Meanwhile, α cells account for approximately 10-30% of pancreatic islets and secrete glucagon, which is released during starvation and breaks down glycogen stored in the liver to release glucose into the blood in order to maintain normal blood glucose levels. δ cells account for approximately 5-10% of pancreatic islet cells and secrete somatostatin, which further regulates glucose levels. Additionally, epsilon and PP cells secrete ghrelin and pancreatic polypeptide, respectively. Pancreatic polypeptide-producing cells (approximately 5-10% of pancreatic islet cells) release hormones that alter exocrine and gastrointestinal function. Other islet cell types also exist, including endothelial cells, neural cells, and progenitor cells.

[0014] As used herein, "pancreatic islet cells" includes the above-described pancreatic islet cells and pancreatic islet precursor cells, which are precursor cells of pancreatic islet cells. They may also refer to intermediate cells that arise during the process of islet cell development or during the process of differentiation induction from somatic stem cells / pluripotent stem cells before reaching pancreatic islet cells or pancreatic islet precursor cells. Here, "intermediate cells" preferably refer to cells that are committed to differentiating into pancreatic islet cells. Furthermore, in the present invention, pancreatic islet cells may be prepared from islet-like cells or islet precursor-like cells into which a Mycl gene or its gene product has been introduced.

[0015] In type I diabetes, cellular infiltration, primarily composed of lymphocytes, into pancreatic islets is observed shortly after the onset of the disease. Eventually, as beta cells are selectively lost, the volume of the islets decreases and alpha cells become the predominant component. Although the islets have a reserve capacity for insulin secretion, type I diabetes develops when the beta cells are lost and the necessary amount of insulin secretion is no longer observed. On the other hand, in type II diabetes, morphological changes in the islets, such as a significant decrease in the number of beta cells, are generally not observed. In type II diabetes, the primary cause of the disease is a decrease in the blood glucose regulation effect of insulin due to insulin resistance in peripheral tissues.

[0016] In the present invention, the origin or source of the pancreatic islet cells into which the Mycl gene or its gene product is introduced is not limited, and may be primary pancreatic islet cells isolated from an individual's pancreas or pancreatic islet cells cultured by a known culture method. Cultured pancreatic islet cells may include, but are not limited to, established pancreatic islet cell lines and pancreatic islet cells derived from stem cells (e.g., iPS cells, ES cells, somatic stem cells) (see, for example, Kimura, A., et al., Cell Chemical Biology, 2020, doi.org / 10.1016 / j.chembiol.2020.08.018). Furthermore, in the present invention, the islet cells into which the Mycl gene or its gene product is introduced may be islet cells obtained from islet-like cells and / or islet precursor-like cells, or the Mycl gene or its gene product may be repeatedly introduced into islet-like cells and / or islet precursor-like cells into which the Mycl gene has already been introduced. In particular, for the purpose of treating diabetes, either islet cells collected from a donor or stem cell-derived islet cells can be preferably used. The islet cells from the donor used may be either autologous or allogeneic to the recipient. According to the present invention, by introducing the Mycl gene into such islet cells, islet precursor-like cells can be expanded in vitro and then transplanted back into the patient, thereby treating diabetes. In this case, in cases where the islet cells are allogeneic to the patient, they can be used in combination with known methods such as administering an immunosuppressant to the patient as appropriate, matching the HLA type of the transplanted donor tissue with that of the recipient, embedding the donor tissue in alginic acid, an alginic acid derivative, a semipermeable membrane, etc. Furthermore, for transplantation into a patient, the above-mentioned islet-like cells, islet precursor cell-like cells, or cells capable of producing insulin, or any combination thereof, can be used.

[0017] In relation to the above, it has been reported that, at least in mice, when β cells are lost, α cells proliferate, and then some of the α cells transdifferentiate into β cells. Therefore, the pancreatic islets used as a source of islet cells before the introduction of the Mycl gene may be not only pancreatic islets containing a large number of normal β cells, but also pancreatic islets from which most of the β cells have been lost. From this perspective, the present invention can also be used in gene therapy for type 1 diabetes patients who have lost β cells, using islet-like cells or the like introduced with the Mycl gene.

[0018] (3) Pluripotent Stem Cells As used herein, "pluripotent stem cells" refer to cells that have the ability to self-replicate and differentiate, and have the ability to form all the cells that make up a living organism. "Self-renewal ability" refers to the ability of a single cell to create undifferentiated cells identical to itself. "Differentiation ability" refers to the ability of a cell to differentiate. Examples of pluripotent stem cells include, but are not limited to, embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells), Muse cells (Multi-lineage differentiating Stress Enduring cells), spermatogonial stem cells (GS cells), and embryonic germ cells (EG cells). The pluripotent stem cells used in the present invention are preferably ES cells. The origin of the pluripotent stem cells is not particularly limited and may be any of mammals, birds, fish, reptiles, and amphibians. Mammals include primates (such as humans and monkeys), rodents (such as mice, rats and guinea pigs), cats, dogs, rabbits, sheep, pigs, cows, horses, donkeys, goats, ferrets and the like.

[0019] As used herein, "ES cells" refers to pluripotent stem cells that have the potential to differentiate into all tissue cells that constitute an individual, extracted from the early stages of development, and established as a line for in vitro culture. ES cells, like pluripotent stem cells in early embryos, can be proliferated virtually indefinitely while retaining the potential to differentiate into all cells that constitute an individual. Specifically, mouse ES cells were first described in 1981 (Proc. Natl. Acad. Sci. USA 78, 7634-7638, 1981; Nature 292, 154-156, 1981). ES cells are pluripotent and can give rise to all tissue and cell types that constitute an individual. Pluripotent embryonic stem cells have been isolated from a wide variety of species, including rats (Iannaconns et al., Dev. Biol. 163, 288-292, 1994), hamsters (Dev. Biol. 127, 224-227, 1988), rabbits (Mol. Reprod. Dev. 36, 424-433, 1993), birds, fish, pigs (Reprod. Fertil. Dev. 6, 563-568, 1994), cattle (Reprod. Fertil. Dev. 6, 553-562, 1994), and primates (Proc. Natl. Acad. Sci. USA 92, 7844-7848, 1995). ES cells that can be used in the present invention include, but are not limited to, KH2 cells, RF8 cells, JI cells, CGR8 cells, MG1.19 cells, 129SV cells, C57 / BL6 cells, DBA-1 cells, and the like.

[0020] Several research teams have also been successful in isolating ES cells and ES cell-like stem cells from embryonic human tissues. Early success stories include the following: (Science 282, 1145-1147, 1998; Proc. Natl. Acad. Sci. USA 95, 13726-13731, 1998; Nature Biotech., 18, 399-404, 2000). These ES cell lines were established by culturing ICM isolated from blastocysts on feeder cells. Other recent studies have demonstrated that embryos and embryonic cells can be obtained by transferring nuclei from embryos and mature mammalian cells into enucleated oocytes.

[0021] In the present invention, any established ES cell line can be used. Alternatively, to prevent immune rejection when ES cells produced by the method of the present invention are applied to an individual, it is effective to create a cloned embryo using the individual's somatic cells and establish an ES cell line from the cloned embryo. Using this method, it is possible to establish ES cells that have the same genetic elements as the individual.

[0022] Alternatively, it is believed that the creation of somatic cell clones involves a phenomenon known as "initialization," in which the nucleus of a somatic cell introduced into an egg cell changes to a state similar to that of a fertilized egg. It has been reported that ES cells also possess activity similar to that of an egg (Curr. Biol., 11, 1553-1558, 2001). In other words, it is expected that by fusing an individual's somatic cells with ES cells, it will be possible to convert the somatic cells into cells similar to ES cells. Because ES cells can be genetically manipulated in vitro, it is anticipated that this can be done using ES cells in which factors involved in immune rejection, such as MHC genes, have been previously manipulated, thereby avoiding the rejection reaction without resorting to techniques such as the creation of somatic cell cloned embryos.

[0023] As used herein, "induced pluripotent stem (iPS) cells" refers to cells with pluripotency similar to that of ES cells, obtained by introducing genes for transcription factors such as Oct3 / 4, Sox2, Klf4, and c-Myc into somatic cells. Like ES cells, iPS cells can also be expanded indefinitely while maintaining pluripotency.

[0024] A basic technique for producing iPS cells is to introduce four transcription factors, Oct3 / 4, Sox2, Klf4, and c-Myc, into cells using a virus (Takahashi K, Yamanaka S: Cell 126(4), 663-676, 2006; Takahashi, K, et al: Cell 131(5), 861-72, 2007). Examples of cells that can be used to produce iPS cells, i.e., cells from which iPS cells are derived, include lymphocytes (T cells, B cells), fibroblasts, epithelial cells, endothelial cells, mucosal epithelial cells, mesenchymal stem cells, hematopoietic stem cells, adipose stem cells, dental pulp stem cells, and neural stem cells.

[0025] iPS cells can be reprogrammed using methods well known to those skilled in the art, and are outlined, for example, in Addgene's Blog / Post, "Delivery Methods for Generating iPSCs" (https: / / blog.addgene.org / delivery-methods-for-generating-ipscs). Methods for introducing the Mycl gene into iPS cells include, but are not limited to, methods using recombinant viruses (e.g., retroviruses, lentiviruses, adenoviruses, Sendai viruses, etc.), recombinant plasmids, minicircles, or episomes (e.g., oriP / Epstein-Barr nuclear antigen-1 (EBNA1)-based episomal vectors), or methods for directly introducing RNA (including mRNA) encoding the Mycl gene or the Mycl protein itself into cells.

[0026] As used herein, "EG cells" refers to any embryonic germ stem cell prepared from a primordial germ cell, and there are no particular limitations on its origin. Furthermore, as used herein, "GS cells" refer to germ stem cells prepared from testicular germ cells, and are a cell line that allows spermatogonial stem cells (spermatogonial stem cells) to be cultured in vitro (Cell. 119, 1001-1012, 2004). Among GS cells, mGS cells (multipotent germline stem cells) are particularly preferred, as they have properties similar to ES cells and also possess pluripotency.

[0027] (4) Mycl Gene and Its Gene Product The Mycl (also called "L-Myc") gene is a member of the Myc gene family, which includes the c-Myc gene and Mycn ("N-Myc" gene). Like the c-Myc gene, the Mycl gene is an oncogene and is also known as a reprogramming gene. Unlike the c-Myc gene, the Mycl gene has been shown to have little transforming potential (Nakagawa, M., et al., Proc. Natl. Acad. Sci. USA, vol. 107, pp. 14152-14157, 2010). Mouse and human Mycl cDNA sequence information can be obtained by referring to NCBI accession numbers NM 008506 and NM 001033081, respectively, and those skilled in the art can easily isolate the cDNA.

[0028] According to the present invention, it is preferable to use an isolated Mycl gene and its gene product. As described above, the nucleotide sequence of the Mycl gene can be identified by its NCBI accession number. Usable Mycl genes also include single-stranded or double-stranded DNA and its RNA complement. Examples of DNA include naturally occurring DNA, recombinant DNA, chemically synthesized DNA, DNA amplified by PCR, chemically modified DNA, and combinations thereof. DNA is preferred as the nucleic acid used in the present invention. As is well known, codons are degenerate, and there are amino acids for which multiple nucleotide sequences exist. However, there are no particular limitations on the type of nucleic acid used, as long as pancreatic islet cells (i.e., pancreatic islet-like cells) into which the Mycl gene has been introduced undergo cell proliferation due to expression of the Mycl gene and insulin production is promoted by cessation of expression.

[0029] In one embodiment, the Mycl gene may comprise / consist of: (1) a nucleic acid comprising or consisting of the nucleotide sequence represented by SEQ ID NO: 1 or 3; or (2) a nucleic acid that hybridizes under stringent conditions with a nucleic acid comprising or consisting of the nucleotide sequence represented by SEQ ID NO: 1 or 3 and encodes a polypeptide that has the function of sustaining and / or promoting the proliferation activity of pancreatic islet-like cells when expression of the Mycl gene is induced; or (3) a nucleic acid that hybridizes under stringent conditions with a nucleic acid comprising or consisting of the nucleotide sequence represented by SEQ ID NO: 1 or 3 and encodes a polypeptide that has the effect of sustaining the proliferation of insulin-producing cells and, consequently, the effect of sustaining the promotion of insulin production as a result of proliferation of pancreatic islet-like cells into which the Mycl gene has been introduced.

[0030] As used herein, "under stringent conditions" means hybridization under moderately or highly stringent conditions. Specifically, moderately stringent conditions can be easily determined by a person skilled in the art based on, for example, the length of DNA. The basic conditions are as described in Sambrook, J. The hybridization conditions for nitrocellulose filters are set forth in "Molecular Cloning, A Laboratory Manual (3rd edition)", Cold Spring Harbor Laboratory, 7:42-7:45 (2001)" and include the use of a pre-wash solution of 5x SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0), hybridization conditions of about 50% formamide, 2x SSC to 6x SSC (or other similar hybridization solutions, such as Stark's solution in about 50% formamide at about 42°C) at about 40-50°C, and wash conditions of 0.5x SSC, 0.1% SDS at about 60°C. Highly stringent conditions can also be readily determined by those skilled in the art based on, for example, the length of the DNA. Generally, such conditions involve hybridization and / or washing at a higher temperature and / or lower salt concentration than moderately stringent conditions, and are defined as, for example, hybridization conditions as described above, with a wash at about 68°C, 0.2xSSC, 0.1% SDS. Those skilled in the art will recognize that temperature and wash solution salt concentration can be adjusted as necessary depending on factors such as probe length.

[0031] Homologous nucleic acids cloned using the above-described nucleic acid amplification reaction or hybridization have at least 30% or more, preferably 50% or more, more preferably 70% or more, even more preferably 90% or more, even more preferably 95% or more, and most preferably 98% or more identity to the nucleotide sequence set forth in SEQ ID NO: 1 or 3, respectively. The percent identity can be determined by visual inspection and mathematical calculation. Alternatively, the percent identity of two nucleic acid sequences can be determined by comparing sequence information using the GAP computer program (GCG Wisconsin Package, version 10.3) described in Devereux et al., Nucl. Acids Res., 12, 387 (1984) and available from the University of Wisconsin Genetics Computer Group (UWGCG).

[0032] In one embodiment, the gene product of the Mycl gene is a polypeptide expressed from the above-described Mycl gene. Typically, the polypeptide may be: (1) a polypeptide comprising or consisting of the amino acid sequence represented by SEQ ID NO: 2 or 4; or (2) a polypeptide having at least 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity with the amino acid sequence represented by SEQ ID NO: 2 or 4 and having the function of sustaining and / or promoting the proliferation activity of pancreatic islet-like cells in a glucose concentration-dependent manner.

[0033] In one embodiment, the gene product of the Mycl gene may be a variant of the polypeptide defined above, and may be an amino acid sequence containing one or more amino acid deletions, substitutions, insertions, and / or additions in the amino acid sequence of SEQ ID NO: 2 or 4. The substitution may be a conservative substitution, in which a specific amino acid residue is replaced with a residue having similar physicochemical characteristics. Non-limiting examples of conservative substitutions include substitutions between aliphatic group-containing amino acid residues, such as substitutions between Ile, Val, Leu, or Ala, and substitutions between polar residues, such as substitutions between Lys and Arg, Glu and Asp, and Gln and Asn.

[0034] Mutants resulting from amino acid deletion, substitution, insertion, and / or addition can be prepared by subjecting the Mycl gene to, for example, site-directed mutagenesis, a well-known technique (e.g., Nucleic Acid Research, Vol. 10, No. 20, pp. 6487-6500, 1982). As used herein, "one or more amino acids" refers to a number of amino acids that can be deleted, substituted, inserted, and / or added by site-directed mutagenesis. Furthermore, as used herein, "one or more amino acids" may refer to one or several amino acids, as the case may be.

[0035] In addition to the above-mentioned site-directed mutagenesis, methods for deleting, substituting, inserting, and / or adding one or more amino acids in the amino acid sequence of a polypeptide while maintaining its activity include a method of treating the gene with a mutagen and a method of selectively cleaving the gene, followed by removal, substitution, insertion, or addition of selected nucleotides, and then ligation. The gene product of the Mycl gene in the present invention may be a polypeptide having the activity of promoting insulin production, which consists of an amino acid sequence in which 1 to 10, preferably 9 or less, 7 or less, 5 or less, 3 or less, 2 or less, and more preferably 1 or less amino acids are deleted, substituted, or added in SEQ ID NO: 2 or 4, but is not limited thereto.

[0036] The variant is further a protein comprising an amino acid sequence having at least 80% or more, preferably 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more amino acid identity with the amino acid sequence of SEQ ID NO: 2, and is a polypeptide having the effect of proliferating pancreatic islet-like cells and / or promoting insulin production.

[0037] The percent identity of two amino acid sequences may be determined by visual inspection and mathematical calculation. Alternatively, the percent identity of two protein sequences may be determined by comparing sequence information using the GAP computer program based on the algorithm of Needleman, S. B. and Wunsch, C. D. (J. Mol. Biol., 48:443-453, 1970) and available from the University of Wisconsin Genetics Computer Group (UWGCG). Preferred default parameters for the GAP program include: (1) the algorithm of Henikoff, S. and Henikoff, J. G. (1970) and the GAP ... (Proc. Natl. Acad. Sci. USA, 89:10915-10919, 1992); (2) a gap weight of 12; (3) a gap length weight of 4; and (4) no penalty for end gaps.

[0038] (5) Introduction of Mycl Gene According to the present invention, the method for introducing the Mycl gene into primary pancreatic islet cells, cultured pancreatic islet cells, or stem cells (e.g., iPS cells, ES cells, somatic stem cells) is not particularly limited, and methods known to those skilled in the art can be used. Gene introduction methods generally include "transformation" or "transfection," which refer to transient or stable genetic changes induced in cells after the incorporation of exogenous nucleic acid (e.g., DNA or RNA foreign to the host cell). Typically, genetic changes can be achieved by incorporating the exogenous nucleic acid into the genome of the host cell, or by transiently or stably maintaining the exogenous nucleic acid as an episomal component or independently. According to the present invention, the introduced Mycl gene may be integrated into the genome of the host cell, present as an episomal component, or present in the cytoplasm as a plasmid or vector containing the gene, as long as the on / off control of the gene expression is possible.

[0039] Typically, a "vector" is used to introduce exogenous nucleic acid (preferably DNA) into a host cell. Vectors generally include viruses, particularly attenuated and / or replication-incompetent viruses. Examples of viral vectors include retroviral vectors, lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, and Sendai viral vectors. Furthermore, vectors may contain regulatory sequences, such as promoters, enhancers, ribosome-binding sequences, terminators, and polyadenylation sites, to enable expression of exogenous nucleic acids. Furthermore, as needed, vectors may contain selectable marker sequences, such as drug resistance genes (e.g., kanamycin resistance genes, ampicillin resistance genes, and puromycin resistance genes), thymidine kinase genes, and diphtheria toxin genes, as well as reporter gene sequences, such as fluorescent proteins, β-glucuronidase (GUS), and FLAG. Here, the term "promoter" is also intended to include promoter components sufficient for promoter-dependent gene expression that is cell-type-specific, tissue-specific, or inducible by external signals or drugs. Such components may be located in the 5' or 3' regions of the native gene. Also, "operably linked" means that the DNA sequence and the control sequence are linked in such a way that expression is possible when the appropriate molecules (e.g., transcriptional activator proteins) are linked to the control sequence.

[0040] Furthermore, vectors can be introduced into host cells by, but are not limited to, electroporation (Meiner, V. et al., Proc. Natl. Acad. Sci. USA, 93:14041-14046 (1996)), calcium phosphate, DEAE-dextran, or methods using lipids for gene transfer (lipofectamine, lipofectin, etc.). Cells into which the vector has been introduced can then be selected based on the characteristics of a marker gene (e.g., a drug resistance gene). Correct homologous recombination in the selected cells can be confirmed by Southern blotting or the like using a portion of the exogenous nucleic acid of interest as a probe. In this way, cells heterozygous for a gene of interest, specifically, a gene in which a marker gene has been knocked into the Mycl gene, can be produced.

[0041] As ES cells, the KH2 strain can be used, which has an Frt sequence downstream of the Cola1 locus and expresses the reverse tetracycline-regulated transactivator M2-rtTA under the control of the endogenous Rosa26 promoter (Beard C, et al., Genesis, vol. 44, pp. 23-28 (2006)). The Mycl gene can be introduced into the ES cells using methods well known to those skilled in the art. For example, the Mycl gene can be inserted into an entry vector, pCR8-GW-TOPO vector (manufactured by Invitrogen Life Technologies), by TA cloning, and then an LR reaction can be carried out between the vector and, for example, a Colla1-TetOP-AttR1-ccdB-AttR2-ires-mCherry vector, and the TetOP-Mycl-ires-mCherry vector can be used as a gene introduction vector. Here, the "TetOP (operon)" sequence in the vector is a sequence (tetracycline response element: TRE) to which a reverse tetracycline-controlled transactivator binds; the reverse tetracycline-controlled transactivator expressed from the host cell in response to a reverse tetracycline such as doxycycline (Dox) added to the cell binds, inducing expression of a gene linked downstream. Furthermore, "ires" (internal ribosome entry site) is an internal ribosome recognition sequence, and "mCherry" is a gene (reporter gene) encoding a red fluorescent protein. By introducing this vector into KH2-ES cells together with a nucleic acid encoding flipase, the Mycl gene can be integrated into the chromosome of the ES cells. In addition to the vector containing "ires-mCherry" as described above, other vectors that may be used include pBSSK(-)-IRES-βgeo containing an "ires-βgeo (a fusion gene of β-galactosidase and neomycin resistance gene) cassette" (Mountford P. et al., Proc. Natl. Sci. USA, 91:4303-4307 (1994)) containing a resistance gene, and a similar vector containing an IRES-Hygro (hygromycin resistance gene) cassette.

[0042] The present invention allows the proliferation of pancreatic islet-like cells and their differentiation into insulin-producing cells by controlling the transient expression of the Mycl gene. Thus, the present invention is characterized by the transient expression of the Mycl gene. However, when the Mycl gene is transiently expressed, the number of cells into which the Mycl gene has been introduced relatively decreases as the pancreatic islet-like cells divide, and the expression level of the Mycl gene can be naturally reduced or stopped over time. That is, in one embodiment, the object of the present invention is achieved by "on" control of Mycl gene expression. In another embodiment, it is also possible to forcibly "off" Mycl gene expression (hereinafter referred to as "on / off" control).

[0043] As described above, the use of reverse tetracycline allows for on / off control of the expression of the Mycl gene introduced into host cells. That is, in the presence of reverse tetracycline, the Mycl gene continues to be expressed in the cells, allowing the proliferation of islet-like cells. On the other hand, removal of reverse tetracycline stops the proliferation of islet-like cells and induces their differentiation into insulin-producing cells. In the present invention, the transient expression (on state) of the Mycl gene introduced into the islet-like cells is preferably for a period of at least 2 days to a maximum of 100 days, e.g., 90, 80, 70, or 60 days, from the start of cell culture. On the other hand, it is preferable that the islet-like cells into which the Mycl gene has been introduced proliferate for the above-mentioned period.

[0044] As an alternative means of controlling the on / off of Mycl gene expression, a "photoregulated viral vector" (Tahara, M., et al., PNAS, vol. 116, pp. 11587-11589, 2019) can be used, which allows precise on / off switching of viral vector gene expression and cell proliferation by light irradiation. This is a viral vector in which a gene encoding a photoswitch protein called Magnet has been introduced, and the expression of a target gene incorporated into the vector can be controlled using blue light.

[0045] Other examples of alternative methods for on / off control of Mycl gene expression include episomal vectors (Okita K., et al., Nat Methods 2011 May 8(5):409-412), Sendai virus, and RNA vectors (Warren L., et al., Cell Stem Cell 2010 Nov 7(5):618-630). Non-limiting examples include the methods used for reprogramming (establishing) iPS cells described above (i.e., methods for transiently inducing genes).

[0046] According to the present invention, the object of the present invention can be achieved not only by introducing an isolated exogenous Mycl gene, but also by forcibly expressing an endogenous Mycl gene in a cell. Means for expressing an endogenous Mycl gene include, but are not limited to, a method of forcibly expressing the Mycl gene by replacing the wild-type promoter or enhancer with a strong promoter or enhancer that operably induces expression of the Mycl gene. Examples of promoters used for replacement include the cytomegalovirus (CMV) promoter, which is a strong promoter, and inducible promoters that function in the presence of an inducer. Examples of enhancers used for replacement include the SV40 enhancer, herpes B virus enhancer, cytomegalovirus enhancer, and α-fetoprotein enhancer. In another embodiment, in addition to CRISPR Type II (including CRISPR-dCas9), molecules can be used in which a demethylase, histone modification enzyme, transcription activator, specifically VP64, p65, Rta, etc., capable of activating a promoter and / or enhancer, is attached to the genomic recognition sequence of CRISPR-type I, TALEN, or ZFN. In this specification, the above-mentioned promoters, enhancers, enzymes and factors that activate them, or nucleic acid protein complexes or small molecule compounds may be referred to as "activators" for activating the Mycl gene.

[0047] (6) Introduction of the Mycl gene product The Mycl gene product can be introduced into cells by a common method for introducing foreign genes or proteins into cells, including, but not limited to, a method using a transfection reagent, a method using a virus, electroporation, a particle gun method, sonoporation, liposome fusion, and an introduction method using a micromanipulator or laser light irradiation to form pores in the cell membrane.

[0048] (7) Production of Chimeric Mammals Methods for producing chimeric mammals by introducing ES cells into mammals can be performed using methods well known to those skilled in the art. First, any medium known to those skilled in the art can be used to culture the ES cells into which the Mycl gene has been introduced. For example, when the ES cells are cultured on feeder cells, feeder cells (e.g., MEFs (mouse embryonic fibroblasts)) can be used, and the ES cells on these feeder cells can be cultured in ES cell medium (e.g., a medium prepared by adding 2-mercaptoethanol (2ME, GIBCO) and LIF (SIGMA) to knockout DMEM (GIBCO) containing 15% FBS, 50 U / mL penicillin / streptomycin, L-glutamine, and non-essential amino acids).

[0049] Next, the ES cells are introduced into a mammal to produce a knockout animal (Mycl gene knock-in animal). Here, a mouse will be used as an example of a mammal, but methods for producing knock-in mice are well known to those skilled in the art. Specifically, a chimeric mouse can be produced by injecting the ES cells into a blastocyst of a mouse (e.g., C57BL / 6, etc.) and transplanting it into the uterus of a pseudopregnant female mouse (e.g., ICR). The chimeric mouse can then be mated with a normal mouse (e.g., C57BL / 6, etc.) to produce a heterozygous mutant mouse in which the Mycl gene has been knocked in heterozygously. By mating heterozygous mutant mice with each other, a homozygous mutant mouse in which the Mycl gene has been knocked in homozygously can be obtained. For the production of the above knock-in mice, please refer to ECAT3 knock-in mice (Tokuzawa, Y., et al., Molecular and Cellular Biology, 23(8):2699-2708(2003)), ECAT4 knock-in mice (Mitsui, K., et al., Cell, 113:631-642(2003)), ECAT5 knock-in mice (Takahashi, K., K. Mitsui, and S. Yamanaka, Nature, 423(6939):p541-545(2003), JP 2003-265166 A), etc.

[0050] Furthermore, chimeric mammals can be produced not only using ES cells but also using iPS cells. For example, organs can be produced from human iPS cells in non-human mammals using the blastocyst complementation method. For example, Nakauchi et al. have developed a human pancreas induced from human iPS cells in vivo in an apancreatic cloned pig (see Nakauchi, H., et al., PNAS, Vol. 110, No. 1, 4557-4562 (2013)).

[0051] 2. Control of Proliferation and Differentiation of Islet-Like Cells According to the present invention, the proliferation and differentiation of the islet-like cells prepared as described above can be controlled in vitro and in vivo. The method for inducing the Mycl gene can be selected in accordance with the method used to introduce the gene into cells. For example, when the Mycl gene is introduced into cells using the TetOP-Mycl-ires-mCherry vector described above as a gene transfer vector, a reverse tetracycline-controlled transactivator expressed from host cells in a manner dependent on reverse tetracycline, such as doxycycline (Dox), binds to the Mycl gene, thereby inducing the proliferation of islet-like cells. The concentration of Dox added to the cell culture system can be adjusted appropriately, for example, to 1 to 100 mg / mL. After proliferation of islet-like cells by adding Dox, proliferation can be stopped by, for example, replacing the medium with one lacking Dox, and cell differentiation, such as insulin production, can be induced.

[0052] In vivo, proliferation of pancreatic islet-like cells can be induced in the pancreas by providing a chimeric non-human mammal with, for example, Dox-containing water. The concentration of Dox added to the water may be, for example, 1 to 100 mg / mL, and preferably 2.0 mg / mL. When using a chimeric non-mouse, the pancreas grows with age up to 8 weeks after birth, so Dox can be administered once growth has stopped, for example, after 8 weeks of age. However, the age at which proliferation can be induced is not limited.

[0053] 3. Method for Producing Insulin-Producing Pancreatic Islet Cells or Their Progenitor Cells The present invention provides a method for producing insulin-producing pancreatic islet cells or their progenitor cells. Such production methods include, but are not limited to, using primary pancreatic islet cells, cultured pancreatic islet cells, or stem cell-derived pancreatic islet cells as starting materials, introducing the Mycl gene into the pancreatic islet cells, forcing the cells to express the Mycl gene, and then terminating the expression of the gene to obtain insulin-producing pancreatic islet cells or their progenitor cells. As described above, the forced expression and terminating of the Mycl gene can be achieved, for example, by using alternative means for on / off control of gene expression (e.g., the use of a photoregulated viral vector) or a doxycycline-sensitive reverse tetracycline-regulated transactivator. As used herein, "precursor cells of pancreatic islet cells" or "pancreatic islet progenitor cells" refers to cells (or a group of cells) that are in the process of differentiating into pancreatic islet cells capable of producing insulin after the cessation of expression of the Mycl gene, and can be identified using, for example, one or more markers selected from the group consisting of PDX1-positive, PTF1a-positive, NKX6.1-positive, Fev-positive, Pax4-positive, and Cck gene-positive as indicators.

[0054] 4. Method for Proliferating Islet-Like Cells Previously, the efficiency of expanding mature islet cells by Mycl gene introduction was limited in some cases. In particular, low expansion efficiency was observed when islet-like cell proliferation was performed over a long period of time. According to the present invention, further proliferation of mature islet cells induced by the Mycl gene can be induced by providing a higher glucose stimulation concentration. Therefore, a method for culturing islet cells into which the Mycl gene or its gene product has been introduced or its expression has been induced using a medium containing a high glucose concentration, i.e., a method for sustaining and / or promoting the proliferation activity of islet cells into which the Mycl gene or its gene product has been introduced or its expression has been induced in a glucose concentration-dependent manner, is provided. "Glucose concentration-dependent" means that further proliferation of the islet cells can be induced by a higher glucose stimulation concentration within a certain concentration range (e.g., 10 g / L or less). In one embodiment, islet-like cells are cultured in a medium containing a high glucose concentration (sometimes simply referred to as "high glucose medium") to accommodate transient expression (on state) of the Mycl gene. A high-glucose medium refers to a medium having a glucose concentration of 3 g / L or more, preferably 3.5 to 10 g / L, more preferably 4 to 7 g / L, and even more preferably 4 to 6 g / L.

[0055] In one embodiment using a high-glucose medium, the cells may be cultured in the high-glucose medium for a certain period of time, followed by culture in a low-glucose medium for a certain period of time, and then cultured again in the high-glucose medium for a certain period of time, thereby alternately applying (using) the high-glucose medium and the low-glucose medium. By alternately applying (using) the high-glucose medium and the low-glucose medium, the proliferation activity of the islet-like cells can be maintained over a long period of time. The term "low-glucose medium" is used interchangeably with "low-concentration glucose medium." Specifically, this refers to a medium having a glucose concentration of less than 3 g / L, preferably 0.1 to 2.8 g / L, more preferably 0.5 to 2.5 g / L, and even more preferably 1 to 2 g / L. The timing of the exchange between the high-glucose medium and the low-glucose medium can be adjusted as appropriate, for example, to coincide with the passage timing of the islet-like cells (e.g., but not limited to, once a day, once every two days, once every three days, once every four days, once every five days, once every six days, or once every seven days). By changing the glucose concentration in this way, the proliferation activity of the islet-like cells can be maintained for a long period of time, for example, 1 month or more, 3 months or more, 6 months or more, 8 months or more, or 1 year or more. From the viewpoint of preferably maintaining the function when the islet-like cells are matured into pancreatic islet cells, for example, glucose-dependent insulin secretion ability, the culture period by changing the glucose concentration is less than 1 year, preferably less than 8 months, more preferably less than 6 months, even more preferably less than 3 months, and even more preferably less than 1 month.

[0056] By regulating a pathway activated by glucose, not limited to glucose, it is possible to proliferate pancreatic islet cells into which the Mycl gene or its gene product has been introduced or whose expression has been induced. As used herein, regulating a pathway activated by glucose includes a method of activating a glucose-stimulated activation pathway and a method of alternating periods of activation and non-activation of the glucose-stimulated activation pathway. The glucose-stimulated activation pathway refers to a signal transduction pathway stimulated by glucose, and in one embodiment, refers to the GK pathway. In the present invention, the substance that activates the glucose-stimulated activation pathway, which is added in order to sustain and / or promote the proliferation activity of islet-like cells stimulated by the Mycl pathway in a concentration-dependent manner, is not particularly limited as long as it activates the glucokinase pathway. Examples of the substance include, in addition to the above-mentioned glucose, sucrose, and glucokinase activators (known Cpd A (Merck Millipore, CAS 603108-44-7; Sigma-Aldrich, 346021), glucokinase activator II (Sigma-Aldrich, 500487), glucokinase activator III (Merck Millipore, CAS 300353-13-3; Sigma-Aldrich, 509665), etc.

[0057] High-glucose and low-glucose media can be prepared by appropriately blending commercially available basal cell culture media. Basal cell culture media primarily contain carbon and nitrogen sources, as well as amino acids (e.g., essential amino acids), vitamins (e.g., water-soluble vitamins, fat-soluble vitamins), and other micronutrients, inorganic salts, proteins (e.g., albumin, transferrin, insulin), reducing agents (e.g., glutathione), trace elements (e.g., ammonium metavanadate, manganese chloride, sodium selenite), and other substances (e.g., ethanolamine, hypoxanthine sodium, fatty acids, putrescine, pyruvic acid, thymidine, phenol red). The components and concentrations of these components can be adjusted as needed. The basal medium that can be used to prepare these media can be selected from commercially available basal media containing the above-mentioned concentrations of glucose based on the ingredient list published by the manufacturer. Specific components (e.g., glucose-stimulated activation pathway activators) can be separately prepared and added at preferred concentrations, or customized media can be purchased from a media manufacturer. Examples of basal media that can be used include commercially available DMEM-F12, DMEM, RPMI1640, and the like.

[0058] The basal medium may further contain growth factors. Examples of growth factors that are preferably added include, but are not limited to, EGF, FGF-10, Gastrin, Noggin, R-spondin, and B27 supplement. For example, FGF-10 is generally known to have the effect of proliferating cells (including islet progenitor cells), and whether or not it is added, it can maintain the proliferation activity of islet-like cells by regulating the glucose-activated pathway. Therefore, in the culture method for proliferating islet cells using a glucose-stimulated activation pathway activator described herein, FGF10 may or may not be added, but from the perspective of more stable proliferation, it is preferable to add FGF10.

[0059] It is also possible to expand pancreatic islet cells in vivo into which the Mycl gene or its gene product has been introduced or whose expression has been induced. Specifically, it is sufficient to regulate the pathway activated by glucose in vivo. In one embodiment, instead of "high-glucose medium" and "low-glucose medium," a buffer solution adjusted to the above-mentioned final glucose concentration may be administered to the body. In this case, the term "high-glucose medium" may be replaced with "high-glucose buffer," and the term "low-glucose medium" may be replaced with "low-glucose buffer." The timing of replacement of the applied "high-glucose buffer" and "low-glucose buffer" is not limited, and may be, for example, once a day, once every two days, once every three days, once every four days, once every five days, once every six days, or once every seven days. Furthermore, the buffer solution may be in the form of a drink containing glucose, sucrose, or the like, which is expected to cause a sufficient increase in blood glucose when ingested by the body.

[0060] 5. Pharmaceutical Uses According to the present invention, by controlling the expression of the introduced Mycl gene and regulating the glucose-activated pathway, it is possible to increase the proliferation activity of pancreatic islet-like cells, maintain the proliferation activity of pancreatic islet-like cells for a long period of time, and promote insulin production along with the proliferation of pancreatic islet-like cells. Therefore, in one aspect, there are provided an insulin production enhancer containing, as active ingredients, pancreatic islet-like cells whose proliferation activity has been maintained or promoted for a long period of time by a Mycl gene or its gene product and a glucose-stimulated activation pathway activator such as glucose; a pharmaceutical composition containing the active ingredient and other pharmaceutically acceptable ingredients (e.g., carrier, excipient, disintegrant, buffer, emulsifier, suspending agent, soothing agent, stabilizer, preservative, antiseptic, physiological saline, etc.); a method for preventing and / or treating diabetes patients using the insulin production enhancer or pharmaceutical composition; and use of the Mycl gene and the glucose-stimulated activation pathway activator for producing the insulin production enhancer or pharmaceutical composition.

[0061] In another aspect, there is provided a method (ex vivo method) for transplanting islet-like cells into a subject, which are obtained by controlling the expression of an introduced Mycl gene and regulating a pathway activated by glucose, thereby enhancing the proliferation activity of the islet-like cells and sustaining and promoting the proliferation activity of the islet-like cells for a long period of time, for the purpose of preventing and / or treating diabetes. Note that different aspects of the ex vivo method of the present invention are intended depending on the cells used. For example, examples include: (i) an embodiment in which pancreatic islet-like cells obtained by gene transfer into cells derived from adult pancreatic islets are allogeneically or autologously produced in vitro (a narrowly defined ex vivo method including both); (ii) an embodiment in which pancreatic islet-like cells obtained by inducing differentiation, i.e., pancreatic islet-like cells obtained by introducing the Mycl gene into pancreatic islet cells derived from stem cells (iPS cells, ES cells, somatic stem cells, etc.), are allogeneically or autologously produced in vitro (a broadly defined ex vivo method); (iii) an embodiment in which the Mycl gene is functionally expressed in the above (i) and (ii), resulting in proliferating islet precursor cell-like cells; and (iv) an embodiment in which insulin-producing cells or pancreatic islet cells (not containing the Mycl gene) are generated by differentiation from the above (i) to (iii).

[0062] In one embodiment of the present invention, cells can be transplanted into a patient, regardless of whether the cells are autologous or allogeneic, using a known method, specifically, the methods described in Nature Medicine volume 22, pages 306-311 (2016), doi: 10.1038 / nm.4030, Nature Biomedical Engineering volume 2, pages 810-821 (2018), doi: 10.1038 / s41551-018-0275-1, EBioMedicine 12 (2016) 255-262, doi: https: / / doi.org / 10.1016 / j.ebiom. The pancreatic islets to be transplanted may be encapsulated and administered by the method described in, for example, August 34, 2016. By encapsulating the pancreatic islets to be transplanted, it is possible to avoid the use of immunosuppressants or to reduce the dosage of immunosuppressants.

[0063] In one aspect of the present specification, isolated pancreatic islets can be appropriately gene-edited. The genes to be edited are not particularly limited, but specifically, preferable therapeutic features can be added, such as correcting mutant genes contained in pancreatic islet cells by genome editing, modifying molecules that cause immune responses, such as surface antigens such as HLA and GAD proteins, and inducing immune tolerance by deleting Beta-2 Microglobulin, RFX5, RFXANK, RFXAP, and CIITA genes. The gene editing method is not particularly limited, but specific examples include CRISPR-Cas9, CRISPR-Cas12, TALEN, ZFN, CRISPR-Cas3, CRISPR-Type I-D, MAD7, and variants thereof, as well as transposon vectors such as piggyBAC for expressing functional molecules.

[0064] (1) Applicable Diseases Diseases to which the above-described embodiments can be applied are diseases in which insulin does not function sufficiently in the body. Typical examples of such diseases include conditions with reduced secretion, type I diabetes, insulin-resistant conditions with a relative insulin deficiency, type II diabetes, and type 1.5 diabetes, which is an intermediate condition between type I and type II diabetes. According to the present invention, by controlling the expression of the introduced Mycl gene and regulating the pathway activated by glucose, insulin production can be promoted by pancreatic islet-like cells whose proliferation activity is sustained and promoted over a long period of time, and the present invention has the effect of lowering blood glucose in diabetic patients, for example. The indicated disease typically includes diabetes, but more specifically, diseases, disorders, or symptoms associated with severe hypoglycemia, type 1 diabetes (including slowly progressive type 1 diabetes or type 1.5 diabetes), type 2 diabetes, impaired glucose tolerance, hyperglycemia, dyslipidemia, obesity, or metabolic syndrome, as well as diseases caused by other specific mechanisms or diseases, such as genetic abnormalities involved in pancreatic beta cell function, genetic abnormalities involved in the insulin action transduction mechanism, exocrine pancreatic diseases, endocrine diseases, liver diseases, drug or chemical causes, infectious diseases, rare immune-related pathologies, and gestational diabetes. Furthermore, diabetic complications caused by diabetes (e.g., diabetic retinopathy, diabetic neuropathy, etc.) may also be included. In addition, insulin secretion deficiency resulting from total or partial pancreatectomy associated with pancreatitis or pancreatic cancer may also be included.

[0065] Furthermore, the types of diabetes that can be treated by the methods described herein are not particularly limited, but the methods can provide a treatment that secretes physiological insulin depending on blood glucose levels and is less likely to cause hypoglycemia. For example, when used to treat severe hypoglycemia, methods described in known literature can be used as one embodiment, since those skilled in the art know that donor islets have a significant effect on severe hypoglycemia. The methods described in known literature herein include, but are not limited to, those described in Diabetes Care 2016 Jul; 39(7):1230-1240. , DOI: 10.2337 / dc15-1988, The New England Journal of Medicine. 343(4):230-238. , DOI: 10.1056 / NEJM200007273430401, The New England Journal of Medicine. 355(13): 1318-1330. , DOI: 10.1056 / NEJMoa061267, etc.

[0066] Furthermore, when used in the treatment of type I diabetes, there are no particular limitations. As one embodiment of the treatment for type I diabetes, for example, the number of pancreatic islet cells, pancreatic islet-like cells, pancreatic islet precursor-like cells, or insulin-producing cells contained may be adjusted depending on the insulin, blood glucose, and / or C-peptide levels of a type I diabetic patient at any time, in the fasting state, after a glucose load, and / or after glucagon stimulation, and the dosage of the agent for in vivo treatment may be determined by the methods described herein. Type I diabetic patients who are insulin-depleted are at high risk of developing hypoglycemic symptoms, and from the viewpoint that treatment using the methods described herein is preferable, for example, type I diabetic patients whose blood C-peptide levels in the fasting state and / or after glucagon stimulation are 0.5 ng / mL or less, preferably 0.2 ng / mL or less, and more preferably 0.1 ng / mL or less can be treated. The specific dosage of the agent may be adjusted, for example, based on the transplanted amount of donor pancreatic islets typically transplanted for the treatment of severe hypoglycemia. Specifically, for example, the cells are pancreatic islet cells, pancreatic islet-like cells, pancreatic islet precursor-like cells, or insulin-producing cells equivalent to 500 IEQ / kg or more, preferably equivalent to 1000 IEQ / kg or more, more preferably equivalent to 2000 IEQ / kg or more, and even more preferably equivalent to 5000 IEQ / kg or more.

[0067] Furthermore, when used in the treatment of type II diabetes, there are no particular limitations. For example, in one embodiment, the agent can be used as a therapeutic agent for type II diabetes in an insulin-dependent state where the amount of insulin secreted into the body is insufficient. Specifically, for example, the number of pancreatic islet cells, pancreatic islet-like cells, pancreatic islet precursor-like cells, or insulin-producing cells contained in a type II diabetes patient may be adjusted depending on the insulin, blood glucose level, and / or C-peptide level in the fasting state, after a glucose load, and / or after glucagon stimulation, and the dosage of the agent for in vivo treatment may be determined by the method described herein. From the viewpoint of achieving favorable effects in pathological conditions with insulin deficiency, for example, type II diabetes patients with blood C-peptide levels of 0.5 ng / mL or less, preferably 0.2 ng / mL or less, and more preferably 0.1 ng / mL or less in the fasting state and / or after glucagon stimulation can be treated. The specific dosage of the agent can be adjusted, for example, based on the transplanted amount of donor pancreatic islets typically transplanted for the treatment of severe hypoglycemia. Specifically, for example, the cells are pancreatic islet cells, pancreatic islet-like cells, pancreatic islet precursor-like cells, or insulin-producing cells equivalent to 500 IEQ / kg or more, preferably equivalent to 1000 IEQ / kg or more, more preferably equivalent to 2000 IEQ / kg or more, and even more preferably equivalent to 5000 IEQ / kg or more.

[0068] Furthermore, when used as a therapeutic agent for slowly progressing type I diabetes, the amount of the agent contained can be adjusted depending on the amount of insulin, blood glucose level, and / or C-peptide in the body, as in the case of type I diabetes and / or type II diabetes, but is not limited thereto. In this case, the pancreatic islet cells, pancreatic islet-like cells, pancreatic islet precursor-like cells, or insulin-producing cells expanded by the method of the present specification are preferably derived from the patient's own cells. For example, as one embodiment of the treatment of slowly progressing type I diabetes, preferably, the autoantibodies and HLA types against pancreatic islet cells in the blood are determined in advance, and the patient's own pancreatic islet cells can be expanded by the method of the present specification before or after the patient falls into an insulin-dependent state and / or an insulin-deficient state. This enables treatment without the need for immunosuppressants, and can prevent the patient from transitioning to an insulin-dependent state and / or an insulin-deficient state, or can treat the insulin-dependent state and / or an insulin-deficient state. The determination of whether or not a patient has slowly progressive type 1 diabetes is not particularly limited as long as the type of autoantibody or HLA in the blood against pancreatic islet cells is involved in slowly progressive type 1 diabetes, and examples of such methods include a known method of determining whether or not a patient has multiple or independent positive results for islet-associated autoantibodies such as islet cell antibody (ICA), GAD antibody, insulin autoantibody (IAA), or IA-2 antibody. Furthermore, a known method may be used to determine whether or not a patient has an HLA associated with slowly progressive type 1 diabetes, such as HLA-DR4-DQA1*0301-B1*0401.

[0069] Furthermore, from the viewpoint of the therapeutic effect of donor islets, the ex vivo method is preferred for the treatment of severe hypoglycemia, but the method described herein can also be used to expand islet cells in vivo. Because the expanded islet cells exhibit similar effects to those of the ex vivo method, the in vivo islet expansion method can also be selected as a preferred method for treating severe hypoglycemia, similar to the ex vivo method. Furthermore, for the treatment of type I diabetes, type II diabetes, and slowly progressing type I diabetes, the method of expanding islet cells in vivo can be selected, taking into account the subject's gender, age, weight, condition of the affected area, and the condition of the cells used, as with the ex vivo method. In this case, the method of expanding islet cells in vivo can also be combined with the ex vivo method.

[0070] According to the present invention, such diseases can be prevented and / or treated. As used herein, the term "prevent" refers to preventing or delaying the onset / manifestation of the above-mentioned disease or its symptoms, or reducing the risk of onset / manifestation. "Treatment" includes alleviating (alleviating) symptoms characteristic of the target disease or accompanying symptoms, preventing or delaying the worsening of symptoms, etc. "Prevention" refers to preventing or delaying the onset / manifestation of a disease (disorder) or its symptoms, or reducing the risk of onset / manifestation. On the other hand, "improvement" refers to alleviating (alleviating), improving, remission, or curing (including partial cure) a disease (disorder) or its symptoms.

[0071] (2) Insulin Production Promoters and Pharmaceutical Compositions Insulin production promoters or pharmaceutical compositions containing as active ingredients pancreatic islet-like cells whose proliferation activity has been maintained or promoted for a long period of time by the Mycl gene or its gene product and a glucose-stimulated activation pathway activator of the present invention can be used to prevent and treat the above-mentioned diseases. An example of an islet cell proliferation promoter is an agent that proliferates any one, preferably any two or more, of the pancreatic islet cells α cells, β cells, δ cells, ε cells, and PP cells contained in pancreatic islets. An example of an islet function improver is an agent that, upon administration, improves some or all of the functions of pancreatic islets in vivo. Examples of some of the functions of pancreatic islets include blood glucose regulation by islet cells, blood glucose lowering by insulin, glucose production and release by glucagon, somatostatin's inhibitory effect on gastrin, secretin, insulin, and / or glucagon secretion or nutrient absorption in the digestive tract, appetite regulation by ghrelin, and gallbladder contraction and appetite regulation by pancreatic polypeptide. Furthermore, one embodiment of the insulin production-promoting agent is, for example, an agent that promotes physiological insulin secretion in response to blood glucose levels, which is one of the functions of pancreatic islets in vivo. Furthermore, when provided as a pharmaceutical composition, in addition to the active ingredient, the Mycl gene or its gene product used in the above embodiment, other pharmaceutically acceptable ingredients (e.g., carriers, excipients, disintegrants, buffers, emulsifiers, suspending agents, soothing agents, stabilizers, preservatives, antiseptics, physiological saline, etc.) may be contained. Furthermore, an activator for activating the Mycl gene may also be included, if necessary.

[0072] The pancreatic islet cells derived from a living body into which the Mycl gene or its gene product is introduced may be those of a healthy individual, or may be those of a patient with type I diabetes who has lost some or most of his / her beta cells or a patient with end-stage type II urinary tract disease. In this case, the pancreatic islet cells may be autologous or allogeneic to the recipient.

[0073] The insulin production-promoting agent and pharmaceutical composition of the present invention can be obtained by suspending the above-obtained islet-like cells in, but not limited to, physiological saline or an appropriate buffer solution (e.g., phosphate-buffered saline). The number of cells required for treatment can be obtained by forcibly expressing the Mycl gene and appropriately proliferating the cells.

[0074] Furthermore, when used in insulin production enhancers and pharmaceutical compositions, the insulin production enhancers and pharmaceutical compositions may contain dimethyl sulfoxide (DMSO), serum albumin, etc. to protect the cells, or antibiotics, etc. to prevent bacterial contamination and growth. Furthermore, the insulin production enhancers and pharmaceutical compositions may contain other pharmaceutically acceptable ingredients (e.g., carriers, excipients, disintegrants, buffers, emulsifiers, suspending agents, soothing agents, stabilizers, preservatives, antiseptics, physiological saline, etc.). Those skilled in the art will be able to add these factors and drugs to the insulin production enhancers and pharmaceutical compositions at appropriate concentrations.

[0075] The number of pancreatic islet cells, pancreatic islet-like cells, pancreatic islet precursor-like cells, or insulin-producing cells contained in the insulin production promoter and pharmaceutical composition prepared above can be adjusted as appropriate, taking into consideration the subject's sex, age, weight, condition of the affected area, condition of the cells used, etc., so as to obtain the desired effect (e.g., lowering blood glucose levels) in the prevention and / or treatment of diabetes and related diseases.

[0076] The insulin production-promoting agent and pharmaceutical composition of the present invention can be administered to various subjects, including mammals such as primates, humans, dogs, cats, cows, horses, pigs, and sheep, with humans being preferred. The route of administration to a subject is not limited, but can be parenteral, for example, by injection or infusion, to any location in the body that can respond to glucose. Specifically, the agent can be implanted or administered, for example, into the pancreas, under the kidney capsule, preferably subcutaneously or intraperitoneally, more preferably intravascularly or intravenously, and even more preferably into the portal vein.

[0077] The method for activating the administered Mycl gene in vivo is not limited to, but may utilize the above-described system for "on" control or "on and / or off" control of Mycl gene expression. For example, the above-described "photo-controlled viral vector" (Tahara, M., et al., PNAS, vol. 116, pp. 11587-11589, 2019) may be used.

[0078] Furthermore, when the purpose is to target the Mycl gene to the pancreas, gene transfer can be performed targeting a marker specifically expressed in pancreatic islet cells (e.g., PDX1, C-peptide, insulin, MafA, Mnx1, Pax4, Pax6, NeruroD1, Isl1, Nkx2.2, Ngn3, HNF1a, Foxa2, Nkx6.1, glucagon, Arx, MafB, RFX6, IRX1, IRX2, somatostatin). When selecting a method for expanding pancreatic islet cells in vivo, specific examples of the route of administration to a subject include, but are not limited to, intrapancreatic, subcutaneous, or intraperitoneal administration, preferably intravascular or intravenous, and even more preferably intraperitoneal or intrapancreatic duct administration.

[0079] (3) Treatment Method According to the present invention, there is provided a method for preventing and / or treating a subject with diabetes or a related disease using pancreatic islet-like cells whose proliferation activity has been maintained or promoted for a long period of time by the Mycl gene or its gene product and a glucose-stimulated activation pathway activator. Furthermore, according to the present invention, in the above treatment method, an activator for activating the Mycl gene can be administered, and may be administered before, simultaneously with, or after administration of an insulin production-promoting agent or a pharmaceutical composition. Furthermore, in order to expand in vivo pancreatic islet cells into which the Mycl gene or its gene product has been introduced or whose expression has been induced, the concentration of glucose or the like in the body may be adjusted by diet, drinking water, intravenous drip, etc.

[0080] (4) Kit According to the present invention, there is provided a kit for preventing and / or treating diabetes or a disease related thereto, which includes an insulin production enhancer or a pharmaceutical composition. Such a kit may include instructions for administering or transplanting the insulin production enhancer or pharmaceutical composition into a subject. The kit may further include an activator for activating the Mycl gene.

[0081] The present invention will be explained in more detail with reference to the following examples, but the present invention is not limited to these examples in any way.

[0082] Method (i) Establishment of ES cells capable of inducing Mycl expression in a doxycycline (Dox)-dependent manner. The KH2 strain, which has an Frt sequence downstream of the Cola1 locus and expresses the reverse tetracycline-regulated transactivator M2-rtTA under the control of the endogenous Rosa26 promoter, was used as the ES cell for Mycl gene introduction (Beard C, et al., Genesis, vol. 44, pp. 23-28 (2006)). Mycl cDNA was cloned from cDNA derived from the ES cells, and the cloned fragment was inserted into the pCR8-GW-TOPO vector (Invitrogen). The Col1a1-TetOP-Mycl-ires-mCherry vector (hereafter referred to as the "targeting vector") was prepared by performing an LR reaction between the pCR8-Mycl-TOPO vector, into which the Mycl gene had been inserted, and the TetOP-AttR1-ccdB-AttR2-ires-mCherry vector. The Col1a1-TetOP-Mycl-ires-mCherry vector was then inserted into the Col1a1 locus of KH2-ES cells using the flip-in recombination system (Beard et al., 2006). When performing flip-in recombination, 50 μg of the targeting vector into which the Mycl gene had been inserted, 25 μg of the pFlapase vector, and a cell suspension prepared in high-glucose DMEM (Nacalai Tasque) medium containing 25 mM HEPES buffer (Gibco) were electroporated into KH2-ES cells using a Genepulser Xcell electroporation system (BIO-RAD) (voltage: 550 V, capacitance: 25 μF, resistance: ∞, cuvette: 4 mm or more, pulsed twice). 24 hours after electroporation, the cells were selected with 150 μg / mL of hygromycin B (Roche), and the formed colonies were picked up to establish an ES cell line capable of inducing expression of the Mycl gene in a Dox-dependent manner.

[0083] (ii) Cell Culture Method Feeder cells (MEF; mouse embryonic fibroblasts) were cultured in DMEM (Nacalai Tesque) medium containing 10% FBS (GIBCO), 50 U / mL Penicillin-Streptomycin (P / S; Nacalai Tesque), L-glutamine (GIBCO), and NEAA (Nacalai Tesque).

[0084] ES cells were cultured in a medium prepared by adding 2-mercaptoethanol (2ME: GIBCO) and LIF (SIGMA) to knockout-DMEM (GIBCO) containing 15% FBS, 50 U / mL P / S, L-glutamine, and NEAA, and cultured in a gelatin-coated (SIGMA) dish seeded with feeder cells. For subculture, ES cells were treated with 0.25% trypsin / 1 mM EDTA (GIBCO) at 37°C for approximately 3 minutes, and approximately 1 / 10 the volume of the cell suspension was seeded onto a new dish.

[0085] (iii) Generation of mice (KH2-Mycl) capable of inducing Mycl expression in vivo. ES cells capable of inducing Mycl expression in a Dox-dependent manner (Sigma-Aldrich) were injected into mouse blastocysts (ICR, E3.5), and these were then transplanted into the uterus of pseudopregnant mice (Slc: ICR, Shimizu Experimental Materials) on day 2 of pregnancy to generate chimeric mice harboring cells capable of inducing Mycl expression in a Dox-dependent manner. Administration of Dox enabled the mice to induce the expression of the Mycl gene and the red fluorescent protein mCherry throughout their bodies.

[0086] (iv) Mice capable of tracking pancreatic islet cells (Ins1-ires-CreERT2; Gcg-CreERT2, Sst-ires-CreERT2) Mice were generated in which tamoxifen-inducible Cre recombinase (CreERT2) was introduced downstream of the endogenous promoter of the Gcg gene, which is expressed specifically in α cells, and downstream of the endogenous genes for the Ins1 gene, which is expressed specifically in β cells, and the Sst gene, which is expressed specifically in δ cells.

[0087] (v) Administration of Doxycycline Eight-week-old mice were administered a solution containing 2.0 mg / mL of Dox in their drinking water. For cultured cells, doxycycline was added to the medium to a final concentration of 2.0 μg / mL.

[0088] (vi) Preparation of pathological specimens from mouse organs After dissection of the mice, each organ was shaken in 4% PFA (Wako Pure Chemical Industries, Ltd.) for one day, and the next day transferred to 70% EtOH (diluted from 100% EtOH (Wako Pure Chemical Industries, Ltd.) and shaken for another day. The next day, blocks were prepared using a Spin Tissue Processor STR120 (Thermo SCIENTIFIC) according to the recommended protocol. Preparation of pathological specimens was outsourced to Biogate Co., Ltd.

[0089] (vii) Immunostaining Tissue sections were immersed in xylene (Wako Pure Chemical Industries, Ltd.) and then 100% EtOH (Wako Pure Chemical Industries, Ltd.) for at least 30 minutes each. After approximately 10 minutes of washing with tap water, the sections were transferred to boiling antigen retrieval solution pH 9 (Nichirei Biosciences, used at a 10-fold dilution) and subjected to antigen retrieval for 10 minutes. 200 μL of primary antibody solution diluted with blocking solution (2% BSA + 1× PBS) at various dilutions was added to the tissue sections and allowed to stand for 30 minutes to 1 hour. After washing twice with 1× PBS, two drops of secondary antibody solution were added to the tissue sections and allowed to stand for 30 minutes. After washing twice with 1x PBS, in the case of DAB staining, 150 μL of DAB solution (using a DAB substrate kit from Nichirei Biosciences, prepared by adding one drop each of Reagent A and B to 1 mL of Elixir water and mixing, followed by adding one drop of Reagent C) was added to the tissue section, and an antigen-antibody reaction was carried out, followed by observation under a microscope.In the case of fluorescent staining, one drop of mounting material was added to the tissue section, and a cover glass was placed over it, followed by observation under a microscope.

[0090] <Primary antibodies (dilution ratio)-secondary antibodies used> Anti-mCherry antibody (abcam, 1 / 500)-anti-rabbit IgG antibody (Nichirei Biosciences) Anti-Synaptophysin antibody (abcam, 1 / 500)-anti-rabbit IgG antibody (Nichirei Biosciences) Anti-Chromogranin A antibody (DAKO, 1 / 500)-anti-rabbit IgG antibody (Nichirei Biosciences) Anti-Ki67 antibody (abcam, 1 / 200)-anti-rabbit IgG antibody (Nichirei Biosciences) Anti-insulin antibody (DAKO)-anti-guinea pig IgG antibody (BIOTIUM) Anti-Somatostatin antibody (Santa Anti-mouse IgG antibody (BIOTIUM, 1 / 300) - Anti-glucagon antibody (Santa Cruz, 1 / 300) - Anti-mouse IgG antibody (BIOTIUM)

[0091] (viii) RNA recovery, RNA extraction, and cDNA synthesis. For RNA recovery, the cultured cells were washed with PBS(-) (Nakarai Tasque) and then lysed with 350 μL of LBP buffer. RNA was extracted using NucreoSpin® RNA Plus (TAKARA) according to the recommended protocol. cDNA was synthesized using the Primescript single-stranded cDNA synthesis kit (TAKARA) according to the recommended protocol.

[0092] (ix) qRT-PCR: GoTaq qPCR Master Mix (Promega) was used according to the recommended protocol. Analysis was performed using the Stepone Plus system (Life Technologies). The primers and PCR reaction conditions used were as follows:

[0093]

[0094] (b) PCR reaction conditions: 95°C, 2 minutes; 95°C (15 seconds), 60°C (1 minute) [40 cycles]; 95°C (15 seconds), 60°C (1 minute), 95°C (15 seconds).

[0095] (x) Pancreatic Islet Isolation Eight-week-old KH2-Mycl mice were anesthetized by intraperitoneal injection of Somnopentyl (Kyoritsu Pharmaceutical Co., Ltd.). After laparotomy, the opening of the duodenum-common bile duct was identified, and the upper part of the common bile duct and intestine were clamped with bulldog clamps. An incision was made in the common bile duct at its border with the duodenum, and 2 mL of M199 medium (Gibco) containing Colalgenase P (Roche) (2 mg / mL) was injected. The pancreas was then removed, transferred to a 50 mL tube, and digested in a 37°C water bath for 14 minutes and 30 seconds. The pancreas was suspended in 25 mL of cold M199 medium containing 10% FBS and centrifuged twice (1000 rpm, 4°C, 2 minutes). The supernatant was discarded, and the cells were suspended in 10 mL of Histopaque (Sigma). Then, 10 mL of cold M199 medium containing 10% FBS was poured over the suspension and centrifuged (1000 rpm, 4°C, 30 minutes). The supernatant was transferred to another 50 mL tube, and 25 mL of M199 medium containing 10% FBS was added. The islets were then isolated by density gradient centrifugation (1000 rpm, 4°C, 2 minutes) using Lymphoprep.

[0096] (xi) Dispersion of Pancreatic Islets The isolated pancreatic islets were collected in a 1.5 mL silicon tube, and 100 μL of dispersion buffer (see Table 2 below) was added. After standing at 37° C. for 15 minutes, the islets were dispersed by pipetting.

[0097]

[0098]

[0099] (x) Primary mouse islet cell culture The isolated islets were transferred to a 1.5 mL tube, and islet cells were separated using TrypLE. After washing with RPMI medium, the cell count was measured. The islet cells were seeded onto a 96-well plate, and 30 μL of Matrigel was added. The cells and Matrigel were mixed using the tip of a pipette, and the 96-well plate was then heated in CO 2 The gel was allowed to crosslink by standing in an incubator at 37°C for 30 minutes. Then, 120 μL of medium was added, and the mixture was incubated at 37°C in 5% CO 2 The islet cells were cultured at 100°C for 1 hour. KEYENCE BZ-710 was used for observation and imaging of the islet cells.

[0100] (xi) Passage of pancreatic islet cells 120 μL of TrypLE was added to the Matrigel in which the pancreatic islet cells were cultured, and the gel was disrupted by pipetting. The pancreatic islet cells were transferred to a 1.5 mL tube, and 300 μL of TrypLE was added. 2 The cells were incubated in an incubator at 37°C for 10 minutes. Then, they were centrifuged at 200g for 2 minutes, washed with RPMI medium, and counted. The islet cells were seeded onto a 96-well plate and subsequently cultured in three dimensions using Matrigel. The islet cells were passaged once a week in RPMI 1640 (Nacalai Tasque; 09892-15) supplemented with 45 w / v% D(+)-glucose solution (Wako; 079-05511) to achieve an appropriate final glucose concentration (e.g., 4.5 g / L, 4.5 g / L, etc.).

[0101] (xii) Cell fate tracing experiment. 8-12 week-old lineage-tracing mice (KH2-Mycl; Ins1 / Gcg / Sst-CreERT2; R26-mTmG) were intraperitoneally administered 0.2 mL of tamoxifen (20 mg / mL) five times a week. One week later, pancreatic islets were isolated from the mice. After isolating pancreatic islet cells using TrypLE, 1.0 × 10 5 Cells were seeded onto AggreWell plates at 100 cells / well. 4-OHT (100 nmol / mL) was added to the culture medium and cultured for two days. The islet cells were collected and cultured in three dimensions using Matrigel. After one week, images were taken using a KEYENCE BZ-710 and the percentage of GFP-positive cells was assessed using FACS.

[0102] (xiii) Pancreatic islet cell transplantation experiment. Diabetes was induced in immunodeficient mice (NOD / ShiJic-scid Jcl) by intraperitoneal administration of streptozotocin (100 mg / kg) three times a week. 5 × 10 islet cells (passaged 18 times) were transplanted under the kidney capsule of these mice. 5 The cells were transplanted using a Hamilton syringe. Blood glucose levels were measured weekly and as random blood glucose measurements.

[0103] (ix) Intraperitoneal glucose tolerance test (IPGTT) The Mycl-expressing group and the control group were fasted for 12 to 16 hours. Then, each mouse was weighed, and a D-glucose solution was injected intraperitoneally to give a D-glucose concentration of 2 g / kg (mouse). Blood was collected from the tail of each mouse 15, 30, 60, and 120 minutes later, and blood glucose levels were measured using an Antsense stand (Horiba).

[0104] Example 1: Activation of Mycl-induced islet cell proliferation in a test by glucose Expression of the Mycl gene can be confirmed by expression of the mCherry gene inserted downstream of the Mycl gene. The mCherry gene encodes a red fluorescent protein, and expression of this gene causes cells to turn red. The glucose concentration in the medium was varied to examine differences in the proliferation activity of Mycl-induced islet cells. It was found that culture conditions in a high-glucose medium (D-glucose; 4.5 g / L) increased the proliferation efficiency of Mycl-expressing islet cells compared to culture conditions in a low-glucose medium (D-glucose; 1.0 g / L) (see Figure 1).

[0105] We investigated whether the proliferation of the Mycl-induced islet cells described above was dependent on glucose concentration. Mycl-induced islet cells were cultured in the same manner as described above at glucose concentrations of 1.0, 2.0, and 4.5 g / L, and the culture efficiency was evaluated. Comparison of mCherry expression and relative cell numbers revealed that the proliferation efficiency of Mycl-expressing islet cells increased in a glucose concentration-dependent manner (see Figure 2).

[0106] We used a drug (glucokinase activator; GKA) that activates glucokinase, an enzyme involved in glucose metabolism, to examine the effect of this drug on the proliferation efficiency of Mycl-expressing islet cells. As is clear from Figure 3, the addition of GKA (50 μM) was found to increase the proliferation efficiency of Mycl-expressing islet cells compared to the absence of GKA (DMSO).

[0107] Next, we investigated the effect of a glucokinase inhibitor (GKI), which inhibits the activity of glucokinase, an enzyme involved in glucose metabolism, on the proliferation efficiency of Mycl-expressing islet cells. As is clear from Figure 4, the addition of GKI (10 mM) reduced the proliferation efficiency of Mycl-expressing islet cells compared to the absence of GKI (DMSO).

[0108] Example 2: Activation of Mycl-induced islet cell proliferation in vivo by glucose. Using mice capable of tracking islet cells (Ins1-ires-CreERT2; Gcg-CreERT2, Sst-ires-CreERT2), the activation of Mycl-induced islet cell proliferation in vivo by glucose was investigated. While glucose was added to the medium in Example 1 (in vitro), sucrose (glucose + fructose) was used instead of glucose in this example. Furthermore, islet cell proliferation activity was evaluated by immunostaining. The results are shown in Figure 5. Significant islet cell proliferation was observed in the Dox induction + sucrose administration system compared to other experimental systems. This demonstrates that sucrose (glucose + fructose) administration promotes Mycl gene-induced islet proliferation in vivo.

[0109] Example 3: Effect of continuous culture in the presence of glucose on the proliferation activity of Mycl-induced islet cells The effect of the continuous presence of glucose in the medium on the proliferation activity of Mycl-induced islet cells was examined. A high glucose concentration was used for culture. The cells were passaged a total of four times, with each culture cycle lasting 7 days. It was observed that the activation of cell proliferation by Mycl induction decreased with repeated passages (see Figure 6). This indicates that the proliferation ability of Mycl-expressing islet cells decreases with continued culture, even under culture conditions with a high glucose concentration, suggesting the involvement of so-called "glucostoxicity."

[0110] Example 4: Possibility of Sustained Proliferation of Mycl-Induced Islet Cells by Adjusting Glucose Concentration As shown in Example 3, continuous culture in a medium with a high glucose concentration suggested the involvement of so-called "glucose toxicity." Therefore, we investigated whether cells could be cultured continuously for long periods by adjusting the glucose concentration. Cell proliferation was stimulated by alternating between high and low glucose concentrations every 24 hours. As shown in Figure 7, under these culture conditions, the proliferation activity of Mycl-induced islet cells was found to persist for at least 20 passages (approximately 22 weeks). This demonstrated that alternating high and low glucose conditions (hereinafter referred to as "high-low glucose") maintains the high proliferation potential of Mycl-induced islet cells and enables sustained proliferation induction.

[0111] We investigated the changes in cell proliferation over time by counting the number of Mycl-induced islet cells in a high-glucose / low-glucose culture system. As shown in Figure 8, repeated high-glucose / low-glucose cycles maintained the high proliferation potential of Mycl-induced islet cells, enabling sustained proliferation induction.

[0112] Example 5: Tracking test of pancreatic islet cells The expression of the gene Ins1, which is expressed specifically in beta cells derived from pancreatic islet cells, the gene Gcg, which is expressed specifically in alpha cells, and the gene Sst, which is expressed specifically in pancreatic islet cells, was tracked. Ins1-positive cells (beta cells), Gcg-positive cells (alpha cells), and Sst-positive cells (delta cells) were labeled using standard methods to examine whether each cell proliferated. More specifically, the expression intensity of each gene was compared using the expression of the reporter gene mGFP (see Figure 9). The data in Figure 9 indicate that the Mycl gene promotes the proliferation of mature hormone-producing cells, beta cells, alpha cells, and delta cells.

[0113] Furthermore, when the proliferation efficiency of mature hormone-producing cells was examined by FACS analysis, it was found that Ins1-positive cells (β cells) proliferated more efficiently when cultured under Mycl gene and high glucose concentrations (Figure 10).

[0114] Example 6: Recovery of diabetic mice We examined the effects of Mycl-induced islet cells grown for a long period under high-low glucose conditions (alternating high and low glucose conditions) on blood glucose levels in diabetic mice. As shown in Figure 11, transplantation of Mycl-induced islet cells into diabetic mice normalized blood glucose levels. This resulted in improved glucose tolerance in an intraperitoneal glucose tolerance test (IPGTT), confirming that the long-term grown islet cells have high functionality.

[0115] Summary: Based on the results of the above examples, we first found that the proliferation activity of mature islet cells induced by Mycl gene induction is dependent on glucose concentration (see Figures 1 and 2). Indeed, we demonstrated that glucokinase activators (GKAs), which activate glucokinase, a molecule in the intracellular glucose metabolic pathway, promote islet cell proliferation, while glucokinase inhibitors (GKIs), which inhibit it, suppress it (see Figures 3 and 4). We also demonstrated that expression of the Mycl gene in vivo with glucose supplementation strongly promotes islet cell proliferation (see Figure 5). On the other hand, we found that sustained culture under high-glucose conditions reduces cell proliferation activity due to glucotoxicity (see Figure 6). By alternating high-glucose and low-glucose conditions to avoid glucotoxicity, we demonstrated that high proliferation activity could be maintained for at least six months, and proliferation could be induced for at least six months (see Figures 7 and 8). High glucose promoted mature β cell proliferation (see Figures 9 and 10). The continuously expanded pancreatic islet cells produced insulin in response to glucose in vivo and reduced blood glucose levels in diabetic animal models, demonstrating their high functionality (see Figure 11).

[0116] The present invention enables the induction of sustained proliferation of pancreatic islet cells, and is expected to lead to a complete cure of diabetes through pancreatic islet cell transplantation. Furthermore, by activating the Mycl gene together with glucose in vivo, it is possible to efficiently expand pancreatic islet cells in vivo, and it is expected that diabetes can also be completely cured through gene therapy.

[0117] All publications and patents cited herein are incorporated by reference in their entirety. Although specific embodiments of the invention have been described herein for purposes of illustration, those skilled in the art will readily understand that various modifications may be made therein without departing from the spirit and scope of the invention.

Claims

1. A method for promoting and / or sustaining the proliferation activity of pancreatic islet cells into which the Mycl gene or its gene product has been introduced or whose expression has been induced, by using an activator of a glucose-stimulated activation pathway.

2. The method of claim 1, wherein the glucose-stimulated activation pathway activator is at least one selected from the group consisting of glucose, sucrose, and glucokinase activators.

3. The method according to claim 1 or 2, wherein the Mycl gene comprises: (1) a nucleic acid comprising a base sequence represented by SEQ ID NO: 1 or 3; or (2) a nucleic acid encoding a polypeptide which hybridizes under stringent conditions with a nucleic acid comprising a base sequence represented by SEQ ID NO: 1 or 3 and has the function of sustaining and / or promoting the proliferation activity of pancreatic islet-like cells when expression of the Mycl gene is induced.

4. The method according to claim 1 or 2, wherein the Mycl gene product comprises: (1) a polypeptide comprising an amino acid sequence represented by SEQ ID NO: 2 or 4; or (2) a polypeptide having at least 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity with the amino acid sequence represented by SEQ ID NO: 2 or 4 and having the function of sustaining and / or promoting the proliferation activity of pancreatic islet-like cells.

5. The method according to any one of claims 1 to 4, wherein the Mycl gene is expressed transiently.

6. The method according to any one of claims 1 to 5, wherein a high glucose medium and a low glucose medium are applied alternately.

7. The method according to any one of claims 1 to 6, wherein the pancreatic islet cells are primary islet cells isolated from the pancreas, cultured islet cells, or derived from stem cells.

8. The method according to claim 7, wherein the stem cells are selected from the group consisting of iPS cells, ES cells, and somatic stem cells.

Citation Information

Patent Citations

  • Ecat 5 knockout cell

    JP2003265166A

  • Method for inducing differentiation of embryonic stem cell into insulin-secreting cell, insulin-secreting cell induced by the method and use of the same

    JP2009225661A

  • pancreatic islet-like cells

    JP2009536035A

  • EXVIVO maturation of pancreatic islet cells

    JP2014528725A

  • Screening assay for agents that influence beta cell number and / or phenotype

    WO2015067744A1